Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2025-12-28 @ 11:10 PM
Study NCT ID:
NCT04616534
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-22
First Post:
2020-11-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Fallopian Tube Carcinoma | View |
| None | Advanced Malignant Solid Neoplasm | View |
| None | Advanced Ovarian Carcinoma | View |
| None | Advanced Pancreatic Adenocarcinoma | View |
| None | Advanced Primary Peritoneal Carcinoma | View |
| None | Fallopian Tube High Grade Serous Adenocarcinoma | View |
| None | Metastatic Pancreatic Adenocarcinoma | View |
| None | Ovarian High Grade Serous Adenocarcinoma | View |
| None | Platinum-Resistant Fallopian Tube Carcinoma | View |
| None | Platinum-Resistant Ovarian Carcinoma | View |
| None | Platinum-Resistant Primary Peritoneal Carcinoma | View |
| None | Primary Peritoneal High Grade Serous Adenocarcinoma | View |
| None | Stage II Pancreatic Cancer AJCC v8 | View |
| None | Stage III Fallopian Tube Cancer AJCC v8 | View |
| None | Stage III Ovarian Cancer AJCC v8 | View |
| None | Stage III Pancreatic Cancer AJCC v8 | View |
| None | Stage III Primary Peritoneal Cancer AJCC v8 | View |
| None | Stage IV Fallopian Tube Cancer AJCC v8 | View |
| None | Stage IV Ovarian Cancer AJCC v8 | View |
| None | Stage IV Pancreatic Cancer AJCC v8 | View |
| None | Stage IV Primary Peritoneal Cancer AJCC v8 | View |
| None | Unresectable Pancreatic Adenocarcinoma | View |
Keywords: